[Molecular targets for colon cancer. VEGF, EGFR - and what else?].

摘要: Colorectal cancer (CRC) is the second most common in Germany; there are more than 70,000 new cases annually. It commonly a disease of elderly, and its relative absolute frequency has risen during last decades. CRC remains major clinical health economy challenge. Progress been made patient management treatment. Screening colonoscopy was introduced Germany 2002, five therapeutic agents have approved since 2001, i.e. capecitabine, oxaliplatin, cetuximab, bevacizumab panitumumab; guidelines published, 48 interdisciplinary centres certified compliance with DIN EN ISO 9001:2000. Despite these advancements, targeted treatment still infancy. Until 2007, no predictive biomarkers were used to tailor adjuvant or palliative chemotherapy CRC. KRAS genotyping recently as biomarker, only tumors carrying wildtype found respond panitumumab. Among wildtype, 40-53% (equivalent 20-30% all patients) will benefit from treatment, remainder enrolled for "non-targeted" Thus great need that able at different stages disease.